Table 6. Proportion of subjects in each treatment group meeting specified post-challenge endpoints and apparent efficacy versus Placebo (pooled data).

	Treatment group
	Placebo	15 μg x 2		30 μg x 1		30 μg x 2
	N = 45	N = 19		N = 43		N = 38
Endpoint	No. subjects affected	No. subjects affected	Efficacy %	No. subjects affected	Efficacy %	No. subjects affected	Efficacy %
Any Illness	21	3*	66.2	18	10.3	10	43.6
Any illness and seroconversion	20	2*	76.3	8*	58.1	3*	82.2
Systemic or lower respiratory illness and seroconversion	16	1*	85.2	5*	67.3	2*	85.2
Febrile illness and seroconversion	9	0*	100.0	3	65.1	0*	100.0

Efficacy % = 1- [Attack rate (Vaccinated group)/(Attack rate(placebo group)]

* P<0.05